Market Trends of Acute Pancreatitis Industry
This section covers the major market trends shaping the Acute Pancreatitis Market according to our research experts:
Intravenous Fluids Segment is Expected to Grow Over the Forecast Period
The intravenous-fluid therapy segment is expected to witness significant growth in the acute pancreatitis market over the forecast period owing to factors such as the rising burden of acute pancreatitis, gallstones, and obesity among the population and their risk-associated factors.
Acute pancreatitis is related to heavy fluid loss and dehydration, which can be fatal and may lead to the death of the patient. Intravenous fluid administration in the body keeps the body hydrated and ensures proper blood flow to the rest of the body's organs.
The prevalence of chronic comorbidities is rising globally, and this has been accompanied by a growing interest in how these comorbidities affect patients with acute pancreatitis. For instance, according to a research study published in BioMed Hub in November 2021, it has been observed that gastrointestinal symptoms are associated with pre-existing metabolic syndrome, obesity, diabetes mellitus, and metabolic syndrome in the early stages of acute pancreatitis. Also, according to the article published in PLOS One in June 2021, obesity is considered a significant public health problem in France as it is a risk factor for chronic diseases such as diabetes and hypertension, etc., which in turn have substantial psychological and social consequences. Thus, the high burden of obesity increases the risk of developing pancreatitis due to their overeating habits, which in turn is anticipated to fuel the segment's growth over the forecast period.
Furthermore, as per an article published in the NLM in June 2022, it has been found that fluid resuscitation primarily serves to maintain organ perfusion (hemodynamics) and substrate supply (oxygen, among other things) by administering fluid and electrolytes. Also, doctors can restore fluid losses by delivering intravenous (IV) injections rather than using the enteral route when oral intake is not practical. Thus, the advantages of IV fluid therapy over others are expected to increase its adoption and, hence, segment growth.
Therefore, owing to factors such as the high burden of obesity and the increasing adoption of IV therapy, the studied segment is expected to grow over the forecast period.
North America is Expected to Have the Significant Market Share Over the Forecast Period
North America is expected to witness healthy growth in the acute pancreatitis market over the forecast period. The increasing population of people suffering from acute pancreatitis, the increasing number of obesity and gallstone cases, the increasing number of research studies, the presence of a well-established healthcare infrastructure, and high healthcare spending are all factors contributing to the market's growth.In addition, the rising prevalence of obesity among the population due to their changing lifestyles has increased the risk of developing pancreatic inflammation, which in turn is expected to fuel market growth.
According to an article published by the NLM, in November 2022, acute pancreatitis will be the most prevalent gastrointestinal condition and the main reason for hospitalization in the United States. Also, as per an article published in MedRxiv in July 2022, it has been observed that the prevalence of gallstone disease contributed to approximately 2.2 million ambulatory care visits, 1.1 million emergency department visits, and 615,000 hospital discharges in the United States. In addition, as per the same source, it has been observed that women are more likely to develop gallstones as compared to men.
Furthermore, the increasing research and development activities in the region are anticipated to fuel demand for drug- and device-based therapies for treating acute pancreatitis, thereby fueling market growth. For instance, in December 2022, St. Jude Children's Research Hospital, in collaboration with CalciMedica, Inc., will conduct a Phase I/II clinical study assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase. Also, in April 2022, Boston Children's Hospital, in collaboration with the National Pancreas Foundation, will conduct a Phase II clinical study to assess the efficacy of a first-line analgesic in pediatric patients who present to the emergency department with a diagnosis of acute pancreatitis.
Moreover, the rising company activities in developing effective drugs and devices for the treatment of acute pancreatitis are also contributing to market growth. For instance, in October 2022, Regeneron Pharmaceuticals will conduct a Phase II clinical study evaluating the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia for the prevention of recurrent acute pancreatitis.
Therefore, due to factors such as the high burden of acute pancreatitis and gallstones among the population, growing research and development activities, and rising product launches in the region, the studied market is expected to grow over the forecast period.
